Haemophilia is a rare genetic condition that affects the blood’s ability to clot, leaving those with the condition at risk of excessive bleeding even from minor injuries.
For those living with this genetic condition, it can be challenging to find the right treatment and support. Novo Nordisk, a global healthcare company, is here to help.
What is Haemophilia?
Haemophilia is a genetic condition that affects the blood’s ability to clot, making those with the condition prone to excessive bleeding. There are two types of haemophilia – A and B.
Haemophilia A is more common and is caused by a deficiency in factor VIII, while haemophilia B is caused by a deficiency in factor IX. The severity of the condition is determined by the amount of clotting factor in the blood. Those with mild haemophilia may not experience symptoms until later in life, while severe haemophilia can cause spontaneous bleeding into joints and muscles.
Treatment for Haemophilia
There is currently no cure for haemophilia, but there are treatments available to help manage the condition. The primary treatment for haemophilia is replacement therapy, which involves infusing the missing clotting factor into the bloodstream.
This can help prevent bleeding episodes and reduce the risk of joint damage. There are two types of replacement therapy – prophylactic therapy and on-demand therapy.
Prophylactic therapy involves regular infusions of clotting factor to prevent bleeding episodes, while on-demand therapy is used to treat bleeding when it occurs.
Novo Nordisk’s Role in Supporting Haemophilia Warriors
Novo Nordisk is a global healthcare company that is committed to supporting those living with haemophilia. They offer a range of products and services that can help those with the condition manage their symptoms and improve their quality of life.
Here are some of the ways Novo Nordisk is supporting haemophilia warriors:.
1. Innovative Products
Novo Nordisk offers a range of innovative products that can help those with haemophilia manage their condition. These products include:.
Ninefact
Ninefact is a recombinant Factor IX treatment that is used to control and prevent bleeding episodes in those with haemophilia B.
Related Article
The inspiring stories of everyday heroes living with haemophilia
It has a high-purity formulation and a long half-life, making it an effective treatment option for those with the condition.
NovoEight
NovoEight is a recombinant Factor VIII treatment that is used to control and prevent bleeding episodes in those with haemophilia A.
It has a high-purity formulation and a long half-life, making it an effective treatment option for those with the condition.
Feiba
Feiba is a bypassing agent that is used to control and prevent bleeding episodes in those with haemophilia A and B who have inhibitors.
It is a plasma-derived factor VIII inhibitor bypassing activity, and has been shown to be an effective treatment option for those with the condition.
2. Education and Support
Novo Nordisk is committed to providing education and support to those living with haemophilia. They offer a range of resources, including educational materials, online support groups, and one-on-one support from haemophilia experts.
These resources can help those with the condition better understand their condition and how to manage it effectively.
3. Advocacy
Novo Nordisk is also active in advocating for the haemophilia community. They work closely with patient advocacy groups to raise awareness of the condition and advocate for improved access to treatments and services.
They also sponsor events and activities that bring the haemophilia community together.
Conclusion
Haemophilia is a rare genetic condition that can be challenging to manage. However, with the right treatment and support, those with the condition can lead full and active lives.
Novo Nordisk is committed to supporting the haemophilia community and providing innovative products, education and support, and advocacy efforts to help those with the condition thrive.
